Peer-Reviewed Publication
Arch Bronconeumol2026April 9, 2026Journal Article
Comparison of Lung Cancer Screening Programs in Liver Transplant Recipients and the General Population.
Meylin Caballeros Lam1, Paula Raquel Pujols León2, Mercedes Iñarrairaegui3, Ana Ezponda4, Miguel Sogbe5, Javier J Zulueta6, Juan P de-Torres7, Luis Seijo8, Fernando Rotellar9, Gorka Bastarrika10, Jose I Herrero11
1Department of Radiology, Clínica Universidad de Navarra, Madrid, Spain.
2Department of Internal Medicine, Hospital Universitario Gregorio Marañón, Madrid, Spain.
3Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain; CIBERehd, Madrid, Spain; IdiSNA, Pamplona, Spain.
4Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
5Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain.
6Chief Medical Officer, Qure.ai, India.
7IdiSNA, Pamplona, Spain; Department of Pulmonary, Clínica Universidad de Navarra, Pamplona, Spain.
8Department of Pulmonary, Clínica Universidad de Navarra, Madrid, Spain.
9IdiSNA, Pamplona, Spain; Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
10IdiSNA, Pamplona, Spain; Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
11Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain; CIBERehd, Madrid, Spain; IdiSNA, Pamplona, Spain. Electronic address: iherrero@unav.es.
Abstract
OBJECTIVES: The objectives of this study are to analyse whether liver transplant recipients (LTR) have a higher incidence of lung cancer (LC) compared to a population of high risk smokers enrolled in a LC screening program and to evaluate if LC screening results allow an early diagnosis in LTRs.
METHODS: We conducted a retrospective study comparing LC screening outcomes using low-dose computed to…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans